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Chemoresistancea b s t r a c t
WSB-1 is involved in DNA damage response by targeting homeodomain-interacting protein kinase 2
(HIPK2) for ubiquitination and degradation. Here, we report that hypoxia signiﬁcantly up-regulates
the expression of WSB-1 in human hepatocellular carcinoma (HCC) cells. We also provide evidence
that WSB-1 is a target of hypoxia-inducible factor 1 (HIF-1). Silencing the expression of HIF-1a in
HCC cells by RNA interference abolishes hypoxia-induced WSB-1 expression. Using chromatin
immunoprecipitation and luciferase reporter assays, we identiﬁed a HRE of the WSB-1 gene. More-
over, silencing the expression of WSB-1 by RNA interference rescues HIPK2 expression in hypoxic
HCC cells and promotes etoposide-induced cell death in hypoxic HCC cells. Taken together, these
data shed light on the mechanisms underlying hypoxia-induced chemoresistance in HCC cells.
 2013 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction
The ubiquitin–proteasome pathway which highly controls the
degradation of proteins represents a key mechanism for a variety
of cellular activities, including cell cycle regulation, apoptosis and
even hypoxia response [1]. Ubiquitin E3 ligases act at the ﬁnal step
of a three-enzyme cascade involving the ubiquitin-activating (E1)
and ubiquitin-conjugating (E2) enzymes. The E3 mediates the
transfer of ubiquitin to the substrates that play a central role in
conferring speciﬁcity to the ubiquitination pathway. E3 ubiquitin
ligases have been classiﬁed into three groups: the single-subunit
RING-ﬁnger type, the multisubunit RING-ﬁnger type and the
HECT-domain type [2]. The best known examples of the multisub-
unit RING-ﬁnger type E3s are the SCF (Skp1-Cullin-F-box) and the
ECS (ElonginB/C-Cul2/5-SOCS) ubiquitin ligase complexes [3,4].
The SOCS (suppressor of cytokine signaling) box-containing
proteins function as adaptors that link substrates to the Elon-
ginB/C-Cullin complex. In addition to the SOCS box, SOCS box pro-
teins harbor a variety of protein–protein interaction domains,
including the b-domain, WD40 repeats, and ankyrin motifs [3].
So far, at least 70 proteins have been determined to harbor a C-ter-
minal SOCS box [5]. VHL has been implicated as a SOCS-box pro-
tein, but lacks a C-terminal sequence of the SOCS box. The VHL
protein has multiple functions, but the best recognized andevidently linked to the development of renal cell carcinoma
(RCC) is inhibition of hypoxia-inducible factor (HIF), as well as
plays a role in targeting HIF for ubiquitin-mediated degradation
[6]. VHL speciﬁcally interacts with endogenous Cul2–Rbx1 in
mammalian cells, whereas SOCS-box proteins associate with
Cul5–Rbx2 [7].
WSB-1 and WSB-2 have been classiﬁed as part of a new family
which harbors seven WD40 repeats and an SOCS box in the N
terminus and C terminus of a protein, respectively [8,9]. WSB-1
is involved in DNA damage response by targeting homeodomain-
interacting protein kinase 2 (HIPK2) for ubiquitination and degra-
dation [10]. HIPK2 drives the apoptotic program in response to
DNA-damaging chemotherapeutic drug treatment by phosphory-
lating the tumor suppressor protein p53 at Ser46 [11]. HIPK2 is
reported to be degraded during hypoxia in a proteasome-depen-
dent and partially Siah1-dependent fashion [12]. However,
whether WSB-1 is required for hypoxia induced HIPK2 degradation
is remain unclear.
Hypoxia is a common characteristic of solid tumors. Cancer cells
in hypoxic regions present a clinical challenge because they are
more resistant to radiotherapy and many chemotherapeutic drugs
when compared to cancer cells in normoxic regions, therefore
increasing the probability of tumor recurrence [13,14]. Although
several genes associated with hypoxia-induced chemoresistance
in some types of cancers were suggested [15–18], the underlying
molecular mechanism of hypoxia-induced drug resistance remains
to be elucidated.
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2.1. Cell lines and cell culture
The human p53 wild-type hepatocarcinoma cell lines HepG2
and SMMC-7721 were purchased from the China Center for Type
Culture Collection (CCTCC). These cells were cultured in Dulbecco’s
Modiﬁed Eagle’s Medium (DMEM) supplemented with 10% fetal
bovine serum (FBS), 100 Units ml1 of penicillin and 100 lg ml1
of streptomycin in a 5% CO2 incubator. Desferrioxamine (DFO)
and Dimethyl sulfoxide (DMSO) were purchased from Sigma.
2.2. Antibodies and reagents
The Mouse polyclonal anti-WSB1 antibody (ab68953) was pur-
chased from Abcam. The rabbit polyclonal anti-HIF-1a, GAPDH,
HIPK2 antibodies were purchased from Santa Cruz.
2.3. Small interfering RNA (siRNA) transfection
Cells were grown in a monolayer in 6-well plates until 60–70%
conﬂuent. The siRNAs were purchased from Dharmacon. HIF-1a
pool siRNA: GGACACAGAUUUAGACUUG, GAUGGAAGCACUAG
ACAAA, CGUGUUAUCUGUCGCUUUG, UCACCAAAGUUGAAUCAGA.
WSB-1 pool siRNA: UGGCAUCGCUUCAGAUUUG, CAUUUAUGUC
GCAUGUCAA, GUGCUGGGAUUACAGGCGU, GUGUGUAUUUUUGGG
CCAC. SiRNA transfection was performed according to the manu-
facturer’s instructions. Brieﬂy, cells were plated at a density of
0.5  106 cells/well in 6-well plates. Cells were transfected with
100 nM siRNA duplex mixture for 24 h in the presence of lipofect-
amine RNAiMax (Invitrogen). A non-speciﬁc control siRNA
(UAAGGCUAUGAAGAGAUAC) was also transfected at the same
concentration as the negative control.
2.4. RNA isolation and real-time PCR
Total RNAs from HepG2 and SMMC-7721 cells were isolated by
TRIzol reagent. The extracted RNA was quantiﬁed using an ND-
1000 spectrophotometer (Nanodrop, Wilmington, DE), and com-
plementary single-strand DNA was synthesized as described using
an Omniscript RT kit (Qiagen, Valencia, CA). Real-time PCR was
performed using a SYBR Green Premix Ex Taq (Takara) on Light Cy-
cler 480 (Roche). The interested transcripts expression were nor-
malized to 18s mRNA expression using the DCt method and the
linearized DCt (i.e. 2-DCt) was used for comparative purposes.
The primer sequences were available upon request.
2.5. Luciferase reporter assay
The WSB-1 promoter contained both HRE1 and HRE2 was
ampliﬁed from a human genomic DNA template and inserted into
pGL3 basic vector (Promega). For luciferase reporter assay, HepG2
cells were seeded in 24-well plates and transfected with the indi-
cated plasmids. Cells were harvested 48 h after transfection. Lucif-
erase activity was measured using the Dual Luciferase Reporter
Assay System (Promega, USA).
2.6. ChIP assay
Chromatin immunoprecipitation (ChIP) assay kits were pur-
chased from Upstate. In short, HepG2 cells were ﬁxed with 1%
formaldehyde to cross-link the proteins and DNA, after which
DNA was sheared to fragments of 400–800 bp by sonication in an
ultrasound bath on ice. The chromatin was then incubated and
precipitated with anti-IgG and anti-HIF-1a antibodies. Theimmunoprecipitated DNA fragments were detected by real-time
PCR analysis using primers speciﬁc for HRE1 and HRE2. The primer
sequences for HRE1 is 50-CAGAGGCCTTCAGGTAAGGT-30, 50-AACT
CCCCAGCCCACAAGTA-30, for HRE2 is 50-CATATTAGACCATCCAG
GCC-30, 50-AGACCAAAGTACGGAGTCAA-30.
2.7. Western blotting
Cells were harvested, washed twice with PBS and resuspended
in lysis buffer containing Nonidet P-40 (10 mM HEPES, pH 7.4,
2 mM EGTA, 0.5% Nonidet P-40, 1 mM NaF, 1 mM NaVO4, 1 mM
phenylmethylsulfonyl ﬂuoride, 1 mM dithiothreitol, 50 mg/ml
trypsin inhibitor, 10 mg/ml aprotinin, and leupeptin) and incu-
bated on ice for 30 min. After centrifugation at 12000g for
15 min, the supernatant was transferred to a new tube and the pro-
tein concentration was determined. Equivalent samples were sub-
jected to SDS–PAGE on 10% gels. The gels were transferred to
nitrocellulose membranes and probed with the indicated primary
antibodies. The immunoreactive proteins were visualized by incu-
bating in HRP-conjugated secondary antibodies. The signals were
detected by Millipore SuperSignal HRP Substrate kit according to
manufacturer’s instructions.
2.8. MTT assay
Cells transfected with control and WSB-1 siRNAs were treated
with or without 20 lM etopside and incubated under normoxia
or hypoxia conditions for 24 h. MTT (Sigma) solution in PBS was
added to each well for additional 4 h. The unreactive supernatants
in the well were aspirated after centrifugation and replaced with
DMSO, followed by the measurement of OD492 values on a scan-
ning multi-well spectrophotometer (Multiskan MK3, Thermo
Labsystems).
2.9. Apoptosis assay
Cells were collected and resuspended in 500 ll of 1 binding
buffer, with 5 ll of Annexin V-ﬂuorescein isothiocyanate (FITC)
and 5 ll of propidium iodide per the manufacturer’s protocol (An-
nexin V-FITC Apoptosis Detection Kit; Sigma). Flow cytometry was
used to determine Annexin V-FITC and propidium iodide staining.
Annexin V positive cells were considered apoptosis cells.
2.10. Statistical analysis
All experiments were performed a minimum of 3 times, unless
otherwise stated. Values were shown as mean ± S.E.M. Student’s t
test was used for statistical signiﬁcance to analyze experimental
differences. Two-Way ANOVA was used to analyze experiments in-
volve two factors each with multiple levels. ⁄P value of <0.05 was
considered statistical signiﬁcant.
3. Results
3.1. Hypoxia induces WSB-1 expression in hepatocellular carcinoma
cells
To test whether WSB-1 expression is regulated by hypoxia,
SMMC-7721 and HepG2 cells were incubated under normoxia
(21% O2) or hypoxia (1% O2) for 24 h. The mRNA expression levels
of WSB-1 were detected by real-time PCR. As revealed in Fig. 1A,
WSB-1 mRNA levels were signiﬁcantly increased in the cells under
hypoxic condition. Accordingly, the protein levels of WSB-1 were
also increased in cells under hypoxic condition (Fig. 1B). Adminis-
tration of HepG2 cells with 100 lM the hypoxia-mimetic drug DFO
Fig. 1. Hypoxia induces WSB-1 expression in hepatocellular carcinoma cells. (A) The mRNA levels of WSB-1 in SMMC-7721 and HepG2 cells under normoxia (21% O2) or
hypoxia (1% O2) condition for 24 h were determined by real-time PCR assay. (B) The protein levels of WSB-1 in SMMC-7721 and HepG2 cells under normoxia (21% O2) or
hypoxia (1% O2) condition for 24 h were determined by Western blot (WB) using indicated antibodies. Anti-HIF-1a antibody was used to indicate hypoxia response in HCC
cells. Anti-GAPDH antibody was used as loading controls. (C) The protein levels of WSB-1 in HepG2 cells treated with hypoxia-mimetic agent DFO (100 lM) were determined
by WB. (D) SMMC-7721 cells were cultured under hypoxia condition for the indicated length of time. Lysate of cells were assayed by WB with indicated antibodies.
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mulation (Fig. 1C). Moreover, hypoxia induced the expression of
WSB-1 in SMMC-7721 cells in a time dependent manner
(Fig. 1D). Taken together, these data suggested that WSB-1 was in-
duced by hypoxia in HCC cells.
3.2. Hypoxia-induced WSB-1 expression was mediated by HIF-1
transcriptional factor
HIF-1 is a key transcriptional regulator of the hypoxic response
[19]. To test whether HIF-1 mediates hypoxia-regulated WSB-1
expression, SMMC-7721 and HepG2 cells were transiently transfec-
ted with HIF-1a-expressing plasmid for 36 h. As shown in Fig. 2A
and B, ectopic expression of HIF-1a could signiﬁcantly up-regulate
WSB-1 expression in both cell lines. To avoid the over-expression
effects of HIF-1a and further investigate the role of HIF-1 in the reg-
ulation of the expression of WSB-1, SMMC-7721 cells were trans-
fected with siRNA targeting HIF-1a (HIF-1a-siRNA) to silence
endogenous HIF-1a expression or non-speciﬁc gene (Con-siRNA)
and incubated in hypoxic condition for 24 h. The inhibition rate
was evaluated by both real-time PCR and Western blot (Fig. 2C
and D), respectively. As expected, WSB-1 mRNA and protein levels
weremarkedly decreasedwhen HIF-1awas silenced under hypoxic
condition (Fig. 2E and F). Taken together, these data suggested that
HIF-1 is required for hypoxia-induced WSB-1 expression.
3.3. Identiﬁcation and validation of a functional HRE in WSB-1
promoter region
HIF-1 acts by binding to HIF-responsive elements (HREs) in pro-
moters that contain the sequence 50-NCGTG-30. By analyzing the
WSB-1 gene sequence, we identiﬁed two putative HIF-1 response
elments (HRE) at 0.9–0.3 kb region upstream to the transcription
start site of WSB-1 gene (HRE1-812 50-CACGC-30-807 and HRE2-
339 50-GCGTG-30-334) (Fig. 3A). We generated a human WSB-1
promoter-driven luciferase reporter gene containing both HRE1and HRE2. As expected, WSB-1 promoter activity was increased
under hypoxia stimuli (Fig. 3B). Moreover, HIF-1a induced the
expression of a luciferase gene driven by the genomic fragment
containing HRE2, but not HRE1 (Fig. 3C). In addition, chromatin
immunoprecipitation assays in HepG2 cells revealed that HIF-1a
bound to the genomic region of HRE2, but not HRE1 under hypoxia
condition (Fig. 3D). Taken together, these data suggested that HIF-1
binding to the hypoxia response element on the WSB-1 promoter
was required for WSB-1 induction.
3.4. WSB-1 regulated the abundance of HIPK2 during hypoxia
HIPK2 was reported to be regulated by WSB-1 for ubiquitina-
tion and degradation [12]. It will be interesting to test the relation-
ship between WSB-1 and HIPK2 during hypoxia response.
Consistent with above data, hypoxia induced the expression of
WSB-1 in HepG2 cells in a time-dependent manner (Fig. 4A). How-
ever, in response to hypoxia, the expression of HIPK2 was reduced
and exhibited a noticeable inverse relationship with WSB-1
(Fig. 4A). To further investigate whether HIPK2 is regulated by
WSB-1 during hypoxia, HepG2 cells were transfected with siRNA
targeting WSB-1 to silence endogenous WSB-1 expression. The
inhibition rate was evaluated by both real-time PCR and Western
blot (Fig. 4B and C), respectively. As depicted in Fig. 4D, hypoxia-
reduced HIPK2 expression was almost completely blocked. Taken
together, these data indicated that WSB-1 mediated hypoxia-in-
duced HIPK2 degradation.
3.5. Silencing the expression of WSB-1 sensitized hypoxic HCC cells to
etoposide-induced apoptosis
HIPK2 has been reported to be able to drive the apoptotic pro-
gram in response to DNA-damaging chemotherapeutic drug treat-
ment in both p53- and CtBP-dependent manner [11]. The
degradation of HIPK2 during hypoxia contributed to hypoxia-in-
duced chemoresistance. To investigate whether WSB-1 is also
Fig. 2. Hypoxia-induced WSB-1 expression was mediated by HIF-1 transcriptional factor. (A) HIF-1a plasmid was transfected into SMMC-7721 cells for 36 h. Lysate of these
cells were determined by WB with indicated antibodies. (B) HIF-1a plasmid was transfected into HepG2 cells for 36 h. Lysate of these cells were determined by WB with
indicated antibodies. (C) The mRNA levels of HIF-1a in SMMC-7721 cells transfected with siRNA targeting Control or HIF-1a for 24 h were determined by real-time PCR assay.
(D) The protein levels of HIF-1a in SMMC-7721 cells transfected with siRNA targeting Control or HIF-1a and incubated under hypoxic condition for 24 h were determined by
WB with indicated antibodies. (E) The mRNA levels of WSB-1 in SMMC-7721 cells transfected with siRNA targeting Control or HIF-1a for 24 h were determined by real-time
PCR assay. (F) The protein levels of WSB-1 in SMMC-7721 cells transfected with siRNA targeting control or HIF-1a and incubated under hypoxic condition for 24 h were
determined by WB with indicated antibodies.
Fig. 3. Identiﬁcation and validation of a functional HRE in WSB-1 promoter region. (A) Schematic diagrams of HIF1 consensus HRE sequences and the two putative HREs in
the promoter region of WSB-1. (B) HepG2 cells were transfected with theWSB-1 promoter HRE-luciferase reporter plasmid under normoxia or hypoxia condition for 24 h. The
luciferase activity was measured. Transfection efﬁciency was normalized by Renilla luciferase expression, and the results are presented as activation over that for an empty
vector. (C) HepG2 cells were transfected with the inditcated WSB-1 promoter HRE-luciferase reporter plasmid in the absence or presence of HIF-1a plasmid for 36 h, the
luciferase activity was measured. Transfection efﬁciency was normalized by Renilla luciferase expression, and the results are presented as activation over that for an empty
vector. (D) Anti-IgG and anti-HIF-1a antibodies were used in the ChIP assays using HepG2 cells under hypoxia conditions.
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silenced the expression of WSB-1 in HepG2 cells by previous vali-
dated siRNA. Consistent with previous reports, hypoxic HCC cells
were resistant to etoposide-induced cell death (Fig. 5A and B).However, WSB-1 depletion signiﬁcantly promotes hypoxic HCC
cells to etoposide-induced apoptosis (Fig. 5A and B). Taken
together, these data suggest that WSB-1 plays a role in hypoxia-in-
duced chemoresistance.
Fig. 4. WSB-1 regulated the abundance of HIPK2 during hypoxia. (A) HepG2 cells were cultured under hypoxia condition for the indicated length of time. Lysate of cells were
assayed by WB with indicated antibodies. (B) The mRNA levels of WSB-1 in HepG2 cells under normoxia condition for 24 h were determined by real-time PCR assay. (C) The
protein levels of WSB-1 in HepG2 cells under normoxia condition for 24 h were determined by WB with indicated antibodies. (D) HepG2 cells transfected with siRNA
targeting Control or WSB-1 and incubated under normoxia or hypoxia condition for 24 h. The cell lysate were determined by WB with indicated antibodies.
Fig. 5. Silencing the expression of WSB-1 sensitized hypoxic HCC cells to etoposide-
induced apoptosis. (A) HepG2 cells transfected with siRNA targeting Control or
WSB-1 and incubated under normoxia or hypoxia condition for 24 h. The MTT assay
was used to determine the cell viability of these cells. (B) HepG2 cells transfected
with siRNA targeting Control or WSB-1 and incubated under normoxia or hypoxia
condition for 24 h. The apoptotic cells were detected by Annexin-V and PI staining.
The data presented the percentages of Annexin-V positive cells.
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In this study, we showed that both the mRNA and protein levels
of WSB-1 were markedly increased in human hepatocellular carci-
noma cells in response to hypoxia. Scanning the 50-promoter re-
gion of WSB-1 for the consensus sequence of the HIF-1 responseelement (HRE) has revealed two potential binding sites for HIF-1.
By using luciferase and ChIP assays, we found that WSB-1 was a di-
rect target gene of HIF-1.
Both Siah1 and WSB-1 have been reported to be able to target
HIPK2 for ubiquitination and degradation [10,20,21]. However,
our data clearly showed an inverse relationship between WSB-1
and HIPK2 during hypoxia response and hypoxia-induced HIPK2
decrease was largely abolished by WSB-1 depletion. Moreover,
Siah1 was failed to be induced by hypoxia (our unpublished obser-
vation). Thus, our data indicated that WSB-1 was most likely the
major E3 ligase that governing the abundance of HIPK2 during
hypoxia response.
Given that hypoxia is associated with chemoresistance and that
hypoxia can enhance WSB-1 expression, it is conceivable that
WSB-1 would be an ideal target for rational cancer therapy. Indeed,
silencing the expression of WSB-1 by RNA interference rescued
HIPK2 expression and signiﬁcantly sensitized hypoxic HCC cells
to etoposide-induced apoptosis. Given the role played by HIPK2-
P53 axis in tumor cell response to chemotherapy, it will be inter-
esting to investigate whether P53 has a role in WSB-1-mediated
HCC cells chemoresistance in the future.
In summary, our ﬁndings suggest a molecular mechanism by
which hypoxia could induce HCC cells chemoresistance and sug-
gest that WSB-1-inhibition as a promising approach to sensitize
hypoxic cancer cells to therapy.
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